On-Demand Webinar

治疗蛋白质的药物间相互作用：最新情况与挑战

Therapeutic proteins (TP) - and more specifically monoclonal antibodies - are part of the therapeutic…

Certara2022 年 12 月 5 日

Publication

Establishment of PK-PD model in anti-inflammatory active components in Inula cappa extract based on lipopolysaccharide-induced in vitro inflammation model

Discover how PK‑PD modelling shows anti‑inflammatory components reduce NO and TNF‑α in inflamed cells using…

Certara2022 年 12 月 1 日

Publication

Pharmacokinetics and pharmacodynamics of polymyxin B and proposed dosing regimens in elderly patients with multi-drug-resistant Gram-negative bacterial infections

See how fixed 50–75 mg dosing meets PK/PD targets; albumin has minor PK impact using…

Certara2022 年 11 月 11 日

Publication

Pharmacokinetic and Bioequivalent Study of Potassium Chloride Sustained-Release Tablet Under Different Dietary Conditions in Healthy Chinese Subjects

Learn how urinary potassium excretion comparable across formulations and diets; BE confirmed using Phoenix WinNonlin.

Certara2022 年 11 月 2 日

刊物

Pharmacokinetics of L-Citrulline in Neonates at Risk of Developing Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension.

Find out how short 16‑min half‑life; simulations support 37–52 mg/kg QID dosing using Phoenix WinNonlin.

Certara2022 年 10 月 31 日

Blog

为何应在开始临床研究前选择药物制剂

药物开发者常急于推进发现流程以进入人体试验。Most are…

Certara2022 年 10 月 28 日

Publication

Population Pharmacokinetic Analysis of Valsartan in Healthy Chinese Subjects

Explore how food affects absorption; liver enzymes and creatinine influence clearance in valsartan PopPK using…

Certara2022 年 10 月 26 日

Blog

3 takeaways from the FDA oligo guidance you need to know

In June 2022, the FDA published their first oligonucleotide clinical pharmacology specific guidance . This…

Certara2022 年 9 月 23 日

Publication

Evaluating the efficacy of prototype antiseizure drugs using a preclinical pharmacokinetic approach

Discover how species differences in PK and metabolite ratios explain efficacy variation using Phoenix WinNonlin.

Certara2022 年 9 月 11 日

Publication

Early change in the clearance of pembrolizumab reflects the survival and therapeutic response: A population pharmacokinetic analysis in real-world non-small cell lung cancer patients

See how early clearance drop predicts better response and survival; PopPK built using Phoenix NLME.

Certara2022 年 9 月 6 日

沪ICP备2022021526号

Powered by Translations.com GlobalLink Web Software

临床药理学

治疗蛋白质的药物间相互作用：最新情况与挑战

Establishment of PK-PD model in anti-inflammatory active components in Inula cappa extract based on lipopolysaccharide-induced in vitro inflammation model

Pharmacokinetics and pharmacodynamics of polymyxin B and proposed dosing regimens in elderly patients with multi-drug-resistant Gram-negative bacterial infections

Pharmacokinetic and Bioequivalent Study of Potassium Chloride Sustained-Release Tablet Under Different Dietary Conditions in Healthy Chinese Subjects

Pharmacokinetics of L-Citrulline in Neonates at Risk of Developing Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension.

为何应在开始临床研究前选择药物制剂

Population Pharmacokinetic Analysis of Valsartan in Healthy Chinese Subjects

3 takeaways from the FDA oligo guidance you need to know

Evaluating the efficacy of prototype antiseizure drugs using a preclinical pharmacokinetic approach

Early change in the clearance of pembrolizumab reflects the survival and therapeutic response: A population pharmacokinetic analysis in real-world non-small cell lung cancer patients

订阅时事通讯

快捷链接

解决方案

联系我们